Search clinical trials for: Ustekinumab IV - Responder - Placebo SC (MP)

Total 95 results

Centocor, Inc.

Completed

A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF Therapy

Crohn's Disease

United States, France, United Kingdom, Germany, Spain, Belgium, Israel, Australia, Canada, Netherlands, New Zealand, Austria
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Crohn's Disease | Colitis | Inflammatory Bowel Disease | IBD

United States, France, Poland, United Kingdom, Germany, Spain, Israel, Bulgaria, Serbia, South Africa, Japan, Canada, Australia, Netherlands, Korea, Republic of, Belgium, New Zealand, Brazil, Russian Federation, Austria, Hungary, ... and more
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UNIFI)

Inflammatory Bowel Diseases | Colitis, Ulcerative

United States, Australia, France, Poland, Ukraine, United Kingdom, Belgium, Germany, Israel, Bulgaria, Romania, Serbia, Japan, Canada, Netherlands, Korea, Republic of, New Zealand, Russian Federation, Austria, Hungary, Slovakia, D... and more
Janssen-Cilag Ltd.

Completed

A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease (POWER)

Crohn Disease

United States, Korea, Republic of, Netherlands, France, Austria, Italy, United Kingdom, Germany, Russian Federation, Spain, Czechia, Sweden
Janssen Pharmaceutical K.K.

Terminated

A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments

Dermatomyositis | Polymyositis

Japan
Centocor, Inc.

Completed

A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Participants With Crohn's Disease

Crohn Disease

United States, Canada, Belgium
Janssen Research & Development, LLC

Completed

A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic

United States, Poland, Germany, Spain, Mexico, Australia, Taiwan, Argentina, Hungary
Bayer

Recruiting

A Study to Learn How Safe the Study Treatment BAY2701250 is, How it Affects the Body and How it Moves Into, Through and Out of the Body in Healthy Male Participants When a Single Amount is Given as an Injection Into the Vein (Intravenous Infusion) or Under the Skin (Subcutaneous Injection)

Pulmonary Hypertension Due to Left Heart Disease

Germany
Alexion Pharmaceuticals, Inc.
Syneos Health

Completed

Study of ALXN1820 in Healthy Adult Participants

Healthy

Australia, United Kingdom
Eli Lilly and Company

Completed

A Safety Study of LY3462817 in Healthy Japanese and Non-Japanese Participants

Healthy

United States
Eli Lilly and Company

Completed

A Study of LY3361237 in Healthy Participants

Healthy

United States
Eli Lilly and Company

Completed

A Study of LY3475766 in Healthy Participants

Dyslipidemias

United States
Eli Lilly and Company

Terminated

A Study of LY3478006 in Healthy Participants

Healthy

United States
Eli Lilly and Company

Completed

A Study of LY3375880 in Healthy Participants

Healthy

United States
GlaxoSmithKline

Completed

Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma

Asthma

United States, Argentina, Australia, Canada, France, Germany, Japan, Russian Federation, Spain, Ukraine, Belgium, Chile, Korea, Republic of, Mexico, Italy, United Kingdom
Eli Lilly and Company

Completed

A Study of LY3200327 in Healthy Participants

Healthy

United States
Alexion Pharmaceuticals

Completed

Study of Subcutaneous and Intravenous ALXN1720 With and Without rHuPH20 in Healthy Subjects

Healthy

United Kingdom
Eli Lilly and Company

Terminated

A Safety Study of LY3462817 and LY3509754 in Participants With Psoriasis

Psoriasis

United States, Canada
Biogen

Completed

Phase 1 Subcutaneous Single and Multiple Ascending Dose Study of BG00010 (Neublastin)

Healthy | Painful Lumbar Radiculopathy

Netherlands
Astria Therapeutics, Inc.

Completed

A Study of STAR-0215 in Healthy Adult Participants

Hereditary Angioedema

United States
Prometheus Biosciences, Inc., a subsidiary of Merck...
Altasciences Company Inc.

Completed

Bioavailability of SC Formulation and Japanese Ethnobridging Study for PRA023

Healthy

United States
Kyowa Kirin Co., Ltd.

Terminated

Study of KHK 4323 in Healthy Volunteers and Subjects With Atopic Dermatitis

Atopic Dermatitis

Japan
Eli Lilly and Company

Completed

A Study of LY3461767 in Healthy Participants

Healthy

United States, Singapore
Allakos Inc.

Recruiting

Study to Assess the Safety, Tolerability, Pharmacokinetics and Immunogenicity of AK006 in Healthy Subjects and Subjects With Chronic Spontaneous Urticaria

Healthy Participants | Chronic Spontaneous Urticaria

United States, Canada
Eli Lilly and Company

Completed

A Safety Study of LY3493269 Given as a Single Injection in Healthy Participants

Healthy

Singapore
Eli Lilly and Company

Completed

A Study of LY3002813 in Participants With Alzheimer's Disease

Alzheimer Disease

United States, Japan
Regeneron Pharmaceuticals

Completed

Safety and Tolerability of Regeneron Anti-SARS-CoV-2 Monoclonal Antibody/Ies in Adult Healthy Volunteers as Related to COVID-19

Healthy

Belgium
Eli Lilly and Company

Completed

A Study of LY3316531 in Healthy Participants and in Participants With Psoriasis

Psoriasis

United States
Regeneron Pharmaceuticals

Recruiting

A Trial to Learn if Single Ascending Intravenous (IV) Doses of REGN7508 Are Safe and Well Tolerated, and How it Works in the Body of Healthy Adult Participants

Healthy Volunteer

United Kingdom
Sanofi

Recruiting

Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus (APATURA)

Systemic Lupus Erythematosus

Chile, Brazil, Greece, Italy, Spain, United States, Argentina, Hungary, Mauritius, Mexico, Russian Federation, Turkey, Ukraine, Puerto Rico, Switzerland
MedImmune LLC

Completed

To Evaluate Safety, Pharmacokinetics and Pharmacodynamics of MEDI6012 in Subjects With Stable Coronary Artery Disease

Coronary Artery Disease

United States
Janssen Research & Development, LLC

Completed

Study of Guselkumab and Ustekinumab Following a Single Intravenous or Subcutaneous Administration in Healthy Chinese Participants

Healthy

China
Merck Sharp & Dohme LLC
PPD, Part of Thermo Fisher Scientific

Recruiting

A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

Ulcerative Colitis

United States, Israel, Japan, Korea, Republic of, Switzerland, Chile, Dominican Republic
Eli Lilly and Company

Completed

A Safety Study of LY3462817 in Healthy Participants

Healthy

Singapore
GlaxoSmithKline

Completed

A Safety, Tolerability, Pharmacokinetics (PK) and Target Engagement (TE) Study of GSK3858279 in Healthy Participants and Evaluation of the Efficacy of Repeat Doses in Participants With Osteoarthritis (OA)

Pain, Inflammatory

United Kingdom, Germany, Poland
Ablynx

Completed

Caplacizumab Single and Multiple Dose Study in Healthy Japanese and White Subjects.

Healthy Volunteers

United States
Janssen-Cilag International NV

Completed

A Safety, Tolerability, Pharmacokinetics, and Immunogenicity Study of CNTO 6785 in Healthy Volunteers

Healthy

Belgium
Bausch Health Americas, Inc.

Completed

Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 827

Psoriasis
Sanofi

Active, not recruiting

Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis

Multiple Sclerosis

Bulgaria, Canada, Turkey, Spain, United States, Czechia, France, Germany, Russian Federation, Ukraine
Eli Lilly and Company

Terminated

A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)

Healthy | Mild Cognitive Impairment | Alzheimer's Disease

United States, Japan
Eli Lilly and Company

Recruiting

A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)

Alzheimer's Disease

United States, Japan
Eli Lilly and Company

Completed

A Study of LY2541546 in Healthy Postmenopausal Women

Healthy

United States
Takeda

Completed

Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis

Colitis, Ulcerative

United States, Korea, Republic of, Netherlands, Australia, Denmark, Russian Federation, Spain, Croatia, Israel, Serbia, Bulgaria, Canada, Italy, Poland, Ukraine, Hungary, Belgium, Czechia, Turkey, Germany, Japan, Estonia, Mexico, Romania and more
Eli Lilly and Company

Completed

A Multiple Dose Study of LY2541546 in Healthy Postmenopausal Women

Healthy

United States
Pfizer

Completed

Evaluation Of Safety, Tolerability And Pharmacokinetics Of Single And Multiple Doses Of Compound PF-06823859

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-64232025 in Healthy Participants

Healthy

Belgium
MedImmune LLC

Completed

A Study to Evaluate the Efficacy of MEDI8968 in Chronic Obstructive Pulmonary Disease (SPRING)

Chronic Obstructive Pulmonary Disease

United States, Bulgaria, Czech Republic, Poland, United Kingdom, Philippines, Latvia, Lithuania, Ukraine, Hungary
Akeso

Completed

A Study of AK101 in Subjects With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis

China
Biogen

Completed

Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS) (REFINE)

Relapsing-Remitting Multiple Sclerosis

France, Italy, Spain, Germany, Belgium
MedImmune LLC

Completed

Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis

Multiple Sclerosis, Relapsing Forms

United States, Spain, Poland, Ukraine

Search clinical trials for: Ustekinumab IV - Responder - Placebo SC (MP)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jordan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations